
    
      This will be a multi-center, randomized, double-blinded, vehicle-controlled, parallel group,
      dose-finding study in pediatrics, adolescents and adults (aged 12 to 40 years). The objective
      of this study is to assess the safety and efficacy of various doses of BTX 1503 in subjects
      with moderate to severe acne vulgaris of the face.
    
  